查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1584744

抗高血压药物市场：按药物类别、剂型、适应症、分销管道、最终用户划分 - 全球预测 2025-2030

Antihypertensive Drugs Market by Drug Class, Form, Indication, Distribution Channel, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年抗高血压药物市场规模预估为247亿美元，预估2024年将达257.6亿美元，复合年增长率为4.66%，2030年将达339.9亿美元。

抗高血压药物市场的特点是市场广阔，涵盖旨在控制高血压和相关心血管疾病的多类药物，包括利尿剂、ACE抑制剂、钙通道阻断剂和ARB。高血压通常被称为“沉默的杀手”，其盛行率和潜在的严重健康后果使得这些药物的应用成为必要，这使得它们成为世界各地医疗保健策略的一个组成部分。最终用途主要包括医院、诊所、居家医疗，显示其适用于各种病患群体。影响成长的主要因素包括由于人口变化、生活方式的改变以及心血管健康意识的增强而导致高血压盛行率的增加。世界人口老化是一个主要因素，因为老年人更容易患高血压。药物配方和药物传递的技术进步也刺激了市场的扩张。个人化医疗存在新的机会，药物基因组学可能会带来针对个人遗传特征的更有效的抗高血压治疗方案。此外，扩大新兴市场的医疗保健服务也代表着市场开拓的重大机会。然而，与抗高血压药物相关的副作用以及围绕药物核准的严格监管环境等限制可能会阻碍市场成长。其他挑战包括专利药物对非专利的侵蚀以及替代疗法的竞争，包括生活方式干预和整体方法。需要技术创新的领域包括开发提高疗效同时最大限度减少副作用的联合治疗，以及使用奈米颗粒等新型药物传输系统。此外，阐明抗药性机制的研究可能会带来改善药物反应性的治疗方法。抗高血压药物市场是一个由临床需求、技术创新和经济因素驱动的动态市场，未来的成长预计将透过克服监管挑战、解决患者依从性问题以及开发提高药物疗效和可及性的技术来推动。撬动进步。

主要市场统计
基准年[2023] 247亿美元
预测年份 [2024] 257.6亿美元
预测年份 [2030] 339.9亿美元
复合年增长率（%） 4.66%

市场动态：揭示快速发展的抗高血压市场的关键市场洞察

供需的动态交互作用正在改变抗高血压药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 老年人口增加导致高血压盛行率快速上升
    • 全球医疗保健支出增加
    • 提高消费者早期诊断与治疗意识
  • 市场限制因素
    • 核准流程严格，药品研发成本大
  • 市场机会
    • 介绍一类新型抗高血压药物
    • 新药认证快速增加
  • 市场挑战
    • 对抗高血压药物造成健康损害的担忧

波特五力：驾驭抗高血压药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解抗高血压药物市场的外部影响

外部宏观环境因素在塑造抗高血压药物市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解抗高血压药物市场的竞争状况

抗高血压药物市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来发现自己的竞争定位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵抗高血压药物市场供应商绩效评估

FPNV定位矩阵是评估抗高血压药物市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了抗高血压药物市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，抗高血压药物市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 高血压盛行率迅速上升，老年人口增加
      • 世界各地的医疗费用增加
      • 提高消费者早期诊断与治疗意识
    • 抑制因素
      • 药物研发需要严格的核准流程和庞大的成本。
    • 机会
      • 介绍一类新型抗高血压药物
      • 新药认证快速增加
    • 任务
      • 对抗高血压药物对健康的负面影响的担忧
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依药物类别分類的抗高血压药物市场

  • α阻断剂
  • 血管张力素转化酵素抑制剂
  • 血管收缩素受体阻断剂
  • β受体阻断剂
  • 钙离子通道阻断剂
  • 利尿剂
  • 肾素抑制剂
  • 血管扩张剂

第七章 抗高血压药物市场：依形式

  • 静脉注射
  • 口服锭剂/胶囊
  • 经皮吸收贴片

第八章 依适应症分類的降血压药市场

  • 原发性高血压
  • 次发性高血压

第九章 抗高血压药物市场：按分销管道

  • 离线
  • 在线的

第 10 章 抗高血压药物市场：依最终使用者分类

  • 居家护理设施
  • 医院/诊所

第十一章 北美和南美抗高血压药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太地区降血压药市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲的抗高血压药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Alembic Pharmaceuticals Limited
  • Alkem Laboratories
  • Apikos Pharma
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Centurion Remedies Private Limited
  • Daiichi Sankyo Co., Ltd.
  • Dr. Reddy's Laboratories
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • Glenmark Pharmaceuticals Ltd.
  • Johnson & Johnson Services, Inc.
  • Lupin Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Sanofi SA
  • Saphnix Lifesciences
  • Schwitz Biotech
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • United Therapeutics Corporation
  • Zydus Lifesciences Limited
Product Code: MRR-B16853778279

The Antihypertensive Drugs Market was valued at USD 24.70 billion in 2023, expected to reach USD 25.76 billion in 2024, and is projected to grow at a CAGR of 4.66%, to USD 33.99 billion by 2030.

The market for antihypertensive drugs is characterized by a broad scope encompassing multiple classes of medications, including diuretics, ACE inhibitors, calcium channel blockers, and ARBs, aimed at managing hypertension and associated cardiovascular conditions. Hypertension, often dubbed the "silent killer," necessitates the application of these drugs due to its prevalence and potential for severe health implications, making it integral to healthcare strategies worldwide. The end-use scope primarily spans hospitals, clinics, and home healthcare settings, underscoring its extensive application among varying patient demographics. Key factors influencing growth include increasing incidences of hypertension due to demographic shifts, lifestyle changes, and heightened awareness of cardiovascular health. The aging global population is a significant driver, as older adults are more prone to high blood pressure. Technological advancements in drug formulations and delivery mechanisms also spur market expansion. Emerging opportunities exist in personalized medicine, where pharmacogenomics could guide more effective antihypertensive regimens tailored to individual genetic profiles. Furthermore, expanding healthcare access in developing regions presents a substantial opportunity for market penetration. However, limitations such as the side effects associated with antihypertensive medications and the strict regulatory landscape governing drug approval can hinder market growth. Challenges also arise from the generic erosion of patented medicines and competition from alternative therapies, including lifestyle interventions and holistic approaches. Areas ripe for innovation include the development of combination therapies that enhance efficacy while minimizing side effects and the exploitation of novel drug delivery systems such as nanoparticles. Additionally, research into understanding resistance mechanisms could lead to breakthroughs that improve drug responsiveness. The antihypertensive drug market is dynamic, driven by clinical demand, innovation, and economic factors, with future growth dependent on navigating regulatory landscapes, addressing patient compliance issues, and capitalizing on technological advances to improve drug efficacy and accessibility.

KEY MARKET STATISTICS
Base Year [2023] USD 24.70 billion
Estimated Year [2024] USD 25.76 billion
Forecast Year [2030] USD 33.99 billion
CAGR (%) 4.66%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antihypertensive Drugs Market

The Antihypertensive Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Surging prevalence of hypertension, along with the growing geriatric population
    • Increase in healthcare expenditure worldwide
    • Growing consumer awareness of early diagnosis and treatment
  • Market Restraints
    • Stringent approval process and huge costs involved in drug development
  • Market Opportunities
    • Introduction of a new class of antihypertensive drugs
    • Surge in approvals of novel drugs from regulatory bodies
  • Market Challenges
    • Concern regarding adverse health outcomes of antihypertensive drugs

Porter's Five Forces: A Strategic Tool for Navigating the Antihypertensive Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antihypertensive Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antihypertensive Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antihypertensive Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antihypertensive Drugs Market

A detailed market share analysis in the Antihypertensive Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antihypertensive Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antihypertensive Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antihypertensive Drugs Market

A strategic analysis of the Antihypertensive Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antihypertensive Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alembic Pharmaceuticals Limited, Alkem Laboratories, Apikos Pharma, AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Centurion Remedies Private Limited, Daiichi Sankyo Co., Ltd., Dr. Reddy's Laboratories, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., Glenmark Pharmaceuticals Ltd., Johnson & Johnson Services, Inc., Lupin Ltd., Merck & Co., Inc., Novartis AG, Sanofi S.A., Saphnix Lifesciences, Schwitz Biotech, Sun Pharmaceutical Industries Limited, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., United Therapeutics Corporation, and Zydus Lifesciences Limited.

Market Segmentation & Coverage

This research report categorizes the Antihypertensive Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Alpha-Blockers, Angiotensin Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, Beta-Blockers, Calcium Channel Blockers, Diuretics, Renin Inhibitors, and Vasodilators.
  • Based on Form, market is studied across Intravenous Injections, Oral Tablets/Capsules, and Transdermal Patches.
  • Based on Indication, market is studied across Primary Hypertension and Secondary Hypertension.
  • Based on Distribution Channel, market is studied across Offline and Online.
  • Based on End-User, market is studied across Home Care Facilities and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Surging prevalence of hypertension, along with the growing geriatric population
      • 5.1.1.2. Increase in healthcare expenditure worldwide
      • 5.1.1.3. Growing consumer awareness of early diagnosis and treatment
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent approval process and huge costs involved in drug development
    • 5.1.3. Opportunities
      • 5.1.3.1. Introduction of a new class of antihypertensive drugs
      • 5.1.3.2. Surge in approvals of novel drugs from regulatory bodies
    • 5.1.4. Challenges
      • 5.1.4.1. Concern regarding adverse health outcomes of antihypertensive drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Antihypertensive Drugs Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Alpha-Blockers
  • 6.3. Angiotensin Converting Enzyme Inhibitors
  • 6.4. Angiotensin Receptor Blockers
  • 6.5. Beta-Blockers
  • 6.6. Calcium Channel Blockers
  • 6.7. Diuretics
  • 6.8. Renin Inhibitors
  • 6.9. Vasodilators

7. Antihypertensive Drugs Market, by Form

  • 7.1. Introduction
  • 7.2. Intravenous Injections
  • 7.3. Oral Tablets/Capsules
  • 7.4. Transdermal Patches

8. Antihypertensive Drugs Market, by Indication

  • 8.1. Introduction
  • 8.2. Primary Hypertension
  • 8.3. Secondary Hypertension

9. Antihypertensive Drugs Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Offline
  • 9.3. Online

10. Antihypertensive Drugs Market, by End-User

  • 10.1. Introduction
  • 10.2. Home Care Facilities
  • 10.3. Hospitals & Clinics

11. Americas Antihypertensive Drugs Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Antihypertensive Drugs Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Antihypertensive Drugs Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Alembic Pharmaceuticals Limited
  • 3. Alkem Laboratories
  • 4. Apikos Pharma
  • 5. AstraZeneca PLC
  • 6. Bayer AG
  • 7. Boehringer Ingelheim International GmbH
  • 8. Centurion Remedies Private Limited
  • 9. Daiichi Sankyo Co., Ltd.
  • 10. Dr. Reddy's Laboratories
  • 11. F. Hoffmann-La Roche AG
  • 12. Gilead Sciences, Inc.
  • 13. Glenmark Pharmaceuticals Ltd.
  • 14. Johnson & Johnson Services, Inc.
  • 15. Lupin Ltd.
  • 16. Merck & Co., Inc.
  • 17. Novartis AG
  • 18. Sanofi S.A.
  • 19. Saphnix Lifesciences
  • 20. Schwitz Biotech
  • 21. Sun Pharmaceutical Industries Limited
  • 22. Takeda Pharmaceutical Company Limited
  • 23. Teva Pharmaceutical Industries Ltd.
  • 24. United Therapeutics Corporation
  • 25. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. ANTIHYPERTENSIVE DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTIHYPERTENSIVE DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ANTIHYPERTENSIVE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. ANTIHYPERTENSIVE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTIHYPERTENSIVE DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTIHYPERTENSIVE DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ALPHA-BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ANGIOTENSIN CONVERTING ENZYME INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY BETA-BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DIURETICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY RENIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY VASODILATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INTRAVENOUS INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ORAL TABLETS/CAPSULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY TRANSDERMAL PATCHES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY PRIMARY HYPERTENSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY SECONDARY HYPERTENSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOME CARE FACILITIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 238. ANTIHYPERTENSIVE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 239. ANTIHYPERTENSIVE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023